Peyronie’s Disease: AUA Guideline
Top Cited Papers
- 1 September 2015
- journal article
- practice guideline
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 194 (3), 745-753
- https://doi.org/10.1016/j.juro.2015.05.098
Abstract
Purpose: The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of Peyronie’s disease. Materials and Methods: A systematic review of the literature using the PubMed®, EMBASE® and Cochrane databases (search dates 1/1/1965 to 1/26/15) was conducted to identify peer-reviewed publications relevant to the diagnosis and treatment of PD. The review yielded an evidence base of 303 articles after application of inclusion/exclusion criteria. Results: The systematic review was used to create guideline statements regarding treatment of PD. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high quality evidence; high certainty), B (moderate quality evidence; moderate certainty), or C (low quality evidence; low certainty). Evidence-based statements of Strong, Moderate, or Conditional Recommendation were developed based on benefits and risks/burdens to patients. Additional consensus statements related to the diagnosis of PD are provided as Clinical Principles and Expert Opinions due to insufficient published evidence. Conclusions: There is a continually expanding literature on PD; the Panel notes that this document constitutes a clinical strategy and is not intended to be interpreted rigidly. The most effective approach for a particular patient is best determined by the individual clinician and patient in the context of that patient’s history, values, and goals for treatment. As the science relevant to PD evolves and improves, the strategies presented here will be amended to remain consistent with the highest standards of clinical care.Keywords
This publication has 19 references indexed in Scilit:
- Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trialInternational Journal of Andrology, 2011
- Limited shock wave therapy vs sham treatment in men with Peyronie’s disease: results of a prospective randomized controlled double‐blind trialBJU International, 2010
- Risk Factors for Emotional and Relationship Problems in Peyronie's DiseaseThe Journal of Sexual Medicine, 2008
- The Chronology of Depression and Distress in Men with Peyronie's DiseaseThe Journal of Sexual Medicine, 2008
- Impact of Peyronie's Disease on Sexual and Psychosocial Functioning: Qualitative Findings in Patients and ControlsThe Journal of Sexual Medicine, 2008
- Investigation of the Antifibrotic Effect of IFN-γ on Fibroblasts in a Cell Culture Model of Peyronie's DiseaseEuropean Urology, 2008
- Single-Blind, Multicenter, Placebo Controlled, Parallel Study to Assess the Safety and Efficacy of Intralesional Interferon α-2b for Minimally Invasive Treatment for Peyronie’s DiseaseJournal of Urology, 2006
- The Impact of Intralesional Interferon α–2b Injection Therapy on Penile Hemodynamics in Men with Peyronie’s DiseaseThe Journal of Sexual Medicine, 2005
- Expanding the paradigm for plaque development in Peyronie's diseaseInternational Journal of Impotence Research, 2003
- Fibrin Deposition in Peyronie's Disease PlaqueJournal of Urology, 1997